

## **Editorial Policy for Journal CME Supplements**

*The Oncologist* is a peer-reviewed journal published in 12 issues annually. The Journal also publishes CME supplements that may be supported by unrestricted educational grants. These peer-reviewed supplements may provide CME *AMA PRA Category 1 Credits*<sup>™</sup>. Manuscripts from key conferences dealing with medical and practice issues for surgical, radiation, and medical oncology, or a related group of papers on specific subjects important to the busy practitioner entrusted with the care of adult or pediatric cancer patients, are considered for publication. All candidate manuscripts are submitted exclusively to *The Oncologist*, the holder of the copyright. Authors are required to disclose whether potential conflicts of interest exist that could relate to the topic(s) presented: honorarium/expenses; grants; a consultant role; speakers bureau membership; stock ownership; or other special relationships.

The opinions or views expressed in these peer-reviewed educational supplements are those of the authors and do not necessarily reflect the opinions or recommendations of the guest editors, the educational grant sponsor, the Editors, or the Publisher. All manuscripts are considered for publication only with the authors' full knowledge and consent. Each manuscript is subjected to rigorous, independent peer review by *The Oncologist's* Editorial Board, the decisions of which are final.

The articles in a CME supplement may discuss pharmaceutical products and/or product uses that have not been approved by the United States Food and Drug Administration (FDA) or other regulatory authorities. These opinions are exclusively those of the author(s), and neither the Editors nor the Publisher make any warranty for their accuracy or content. For approved product information, consult the manufacturer's prescribing information or the applicable regulatory authority.

### **Disclosure Statement**

The FDA, in a concept paper, has classified commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is "truly independent" and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported educational material be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty must be fully disclosed to the program's participants.

#### **PUBLISHER:**

**AlphaMed Press** 318 Blackwell St., Suite 260, Durham, North Carolina 27701-2884 USA  
**Telephone:** 919.680.0011 **Fax:** 919.680.4411 **E-mail:** [TheOncologist@TheOncologist.com](mailto:TheOncologist@TheOncologist.com)

## **Editorial Policy for Journal CME Supplements** (continued)

The Editors of *The Oncologist* affirm their commitment to publishing only peer-reviewed manuscripts that are fully in compliance with these FDA strictures. The Editors affirm that the Journal is in compliance with both the letter and the spirit of these wise safeguards.

**Disclaimer:** While the Publisher and Editorial Board make every effort to see that no inaccurate or misleading data, opinion, or statement appears in this Journal, they wish to state that the data and opinions in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the Publisher, Editorial Board, and their respective employees, officers, and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion, or statement. While every effort is made to ensure drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage described within this Journal should be followed only in conjunction with the drug manufacturer's own published literature. It is the responsibility of the treating physician or other healthcare professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. This is particularly serious if the agent to be administered is new or infrequently used. Because of the uniqueness of each patient and the need to take into account a number of concurrent considerations, physicians should use this information only as a general guide to determining the best treatment of each patient.

**PUBLISHER:**

**AlphaMed Press** 318 Blackwell St., Suite 260, Durham, North Carolina 27701-2884 USA  
**Telephone:** 919.680.0011 **Fax:** 919.680.4411 **E-mail:** [TheOncologist@TheOncologist.com](mailto:TheOncologist@TheOncologist.com)